Savara (SVRA) Income towards Parent Company (2010 - 2026)
Savara (SVRA) posted quarterly Income towards Parent Company of -$39.9 million for Q1 2026, down 49.61% year-over-year from -$79.1 million in Q1 2025, and down 28.83% quarter-over-quarter from -$30.9 million in Q4 2025.
Savara (SVRA) Income towards Parent Company (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Income towards Parent Company for 17 consecutive years, with -$39.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 49.61% year-over-year to -$39.9 million; the TTM figure through Mar 2026 stood at -$132.5 million (down 22.48% YoY), while the FY2025 annual figure was -$266.3 million, down 26.49% from the prior year.
- Income towards Parent Company retreated to -$39.9 million in Q1 2026 per SVRA's latest filing, from -$30.9 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$8.6 million in Q1 2022 and bottomed at -$39.9 million in Q1 2026.
- Historically, Income towards Parent Company has averaged -$21.4 million across 5 years, with a median of -$20.3 million in 2024.
- Annual changes were most pronounced in 2022 — Income towards Parent Company advanced 21.11% — and 2024, when it plunged 85.18%.
- Savara's Income towards Parent Company stood at -$11.3 million in 2022, then plunged by 58.9% to -$17.9 million in 2023, then sank by 78.31% to -$31.9 million in 2024, then climbed by 3.15% to -$30.9 million in 2025, then retreated by 28.83% to -$39.9 million in 2026.
- Business Quant data shows SVRA's Income towards Parent Company at -$39.9 million in Q1 2026, -$30.9 million in Q4 2025, and -$30.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.45 Mn |
| Mar 31, 2026 | -39.85 Mn |
| Dec 31, 2025 | -30.94 Mn |
| Sep 30, 2025 | -30.13 Mn |
| Jun 30, 2025 | -31.56 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -31.94 Mn |
| Sep 30, 2024 | -26.06 Mn |
| Jun 30, 2024 | -23.52 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -17.91 Mn |
| Sep 30, 2023 | -18.44 Mn |
| Jun 30, 2023 | -12.70 Mn |
| Mar 31, 2023 | -12.56 Mn |
| Dec 31, 2022 | -11.27 Mn |
| Sep 30, 2022 | -10.96 Mn |
| Jun 30, 2022 | -9.90 Mn |
| Mar 31, 2022 | -8.62 Mn |
| Dec 31, 2021 | -11.18 Mn |
| Sep 30, 2021 | -10.08 Mn |